UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - RADIANT-4

Participants in this study have been diagnosed with cancer and have advanced nonfunctional neuroendocrine tumors. This is a voluntary study to find out if the drug everolimus (Afinitor®) is sage and has beneficial effects in people who have this disease. About 279 patients will join in this study at around 120 research clinics in several countries around the world.

Start Date
January 23, 2013
End Date
May 27, 2013
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Daniel Vaena, MD
Contact Info

Pam Zehr, 319-353-8914

advanced nonfunctional neuroendocrine tumors ; cancer ; everolimus (Afinitor®) ; IRB#201202501 ; phase 3 ; phase III ; vaena ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.